This study aims to expand understanding of how crystalloid fluid impacts sepsis survivors’ lives beyond 30 days.
Aim 1: Determine the most effective crystalloid fluid choice to
minimize sepsis-induced AKI and CKD in PRoMPT BOLUS trial participants
Aim 2: Measure the real-world impact of crystalloid fluid on sepsis-induced AKI and CKD
